[Typical risks in the treatment of acute and chronic liver diseases].
D000728:Androgens / Q000627:therapeutic use; D001201:Ascites / Q000628:therapy; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control; D004232:Diuretics / Q000627:therapeutic use; D004932:Esophageal and Gastric Varices / Q000188:drug therapy; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007010:Hyponatremia / Q000139:chemically induced; D007136:Immunoglobulins / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications; D008107:Liver Diseases / Q000628:therapy*; D010396:Penicillamine / Q000627:therapeutic use; D010536:Peritoneovenous Shunt; D011433:Propranolol / Q000627:therapeutic use; D012306:Risk
D000728:Androgens; D004232:Diuretics; D007136:Immunoglobulins; D002792:Cholestyramine Resin; D002927:Cimetidine; D011433:Propranolol; D010396:Penicillamine
Typische Risiken bei der Behandlung akuter und chronischer Lebererkrankungen.